Full enrollment of 195   subjects in NORSE THREE achieved in less than one month, significantly ahead of schedule All planned clinical trials for ONS-5010/LYTENAVA ™ BLA for wet AMD now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration

Live moderated video webcast discussion among members of management and Key Opinion Leader Firas M. Rahhal, MD on Thursday, October 29th at 10:00 AM ET MONMOUTH JUNCTION, N.J. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical

First subjects have been enrolled in supplemental open-label safety study S tudy being conducted t o ensure the requisite number of patient exposures to ONS-5010 to support   new BLA filing to the FDA in 2021 ONS-5010 , an investigational ophthalmic formulation of bevacizumab- vikg for the

MONMOUTH JUNCTION, N.J. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence

MONMOUTH JUNCTION, N.J. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg (LYTENAVA™) for use in retinal indications (known as ONS-5010).

MONMOUTH JUNCTION, N.J. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence

ONS-5010, an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD, demonstrated safety and efficacy profile consistent with previously published ophthalmic bevacizumab research NORSE 1 results support trial design and inclusion criteria for fully enrolled, ongoing

Successfully completed NORSE 2 enrollment in July 2020 NORSE 1 topline results to be reported in August 2020 MONMOUTH JUNCTION, N.J. , Aug. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first

MONMOUTH JUNCTION, N.J. , July 17, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the successful

Pivotal NORSE 2 safety and efficacy data expected to be reported in the third calendar quarter of 2021   ONS-5010 / LYTENAVA ™   (bevacizumab-vikg)   has the potential to be the first FDA-approved ophthalmic formulation of bevacizumab for use in multiple retinal indications MONMOUTH JUNCTION, N.J.